PURPOSE: To identify biological markers related to the progression and prognosis of GBC. METHODS: The expressions of pyruvate kinase isoenzyme type M2 (PKM2) and activin A receptor type IC (ACVR 1C) in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry. RESULTS: Positive PKM2 and negative ACVR 1C expressions were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASCs and ACs. Univariate Kaplan-Meier analysis showed that either elevated PKM2 or loss of ACVR 1C expression significantly correlated with shorter average survival times in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive PKM2 expression and loss of ACVR 1C expression were poor prognosis biomarkers in both SC/ASC and AC patients. CONCLUSIONS: Our study suggested that PKM2 overexpression is a marker of metastasis, invasion and poor prognosis of GBC. ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of GBC.
PURPOSE: To identify biological markers related to the progression and prognosis of GBC. METHODS: The expressions of pyruvate kinase isoenzyme type M2 (PKM2) and activin A receptor type IC (ACVR 1C) in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry. RESULTS: Positive PKM2 and negative ACVR 1C expressions were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASCs and ACs. Univariate Kaplan-Meier analysis showed that either elevated PKM2 or loss of ACVR 1C expression significantly correlated with shorter average survival times in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive PKM2 expression and loss of ACVR 1C expression were poor prognosis biomarkers in both SC/ASC and AC patients. CONCLUSIONS: Our study suggested that PKM2 overexpression is a marker of metastasis, invasion and poor prognosis of GBC. ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of GBC.
Authors: Juan C Roa; Oscar Tapia; Asli Cakir; Olca Basturk; Nevra Dursun; Deniz Akdemir; Burcu Saka; Hector Losada; Pelin Bagci; N Volkan Adsay Journal: Mod Pathol Date: 2011-04-29 Impact factor: 7.842
Authors: Xabier de Aretxabala; Ivan Roa; Luis Burgos; Hector Losada; Juan Carlos Roa; Javier Mora; Juan Hepp; Jorge Leon; F Maluenda Journal: J Gastrointest Surg Date: 2006-02 Impact factor: 3.452
Authors: Gilles A Spoden; Sybille Mazurek; Dieter Morandell; Nicole Bacher; Michael J Ausserlechner; Pidder Jansen-Dürr; Erich Eigenbrodt; Werner Zwerschke Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: William G Hawkins; Ronald P DeMatteo; William R Jarnagin; Leah Ben-Porat; Leslie H Blumgart; Yuman Fong Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: Eva Angenete; Marcus Langenskiöld; Ingrid Palmgren; Peter Falk; Tom Oresland; Marie-Louise Ivarsson Journal: Int J Colorectal Dis Date: 2007-07-27 Impact factor: 2.571
Authors: M A Hoda; J Münzker; B Ghanim; K Schelch; T Klikovits; V Laszlo; E Sahin; A Bedeir; A Lackner; B Dome; U Setinek; M Filipits; M Eisenbauer; I Kenessey; S Török; T Garay; B Hegedus; A Catania; S Taghavi; W Klepetko; W Berger; M Grusch Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640